Disposition of valproic acid in patients with liver disease.

European journal of clinical pharmacology ·Vol. 13 ·No. 1 ·1978-03-17 ·Pages 55-60

Klotz U, Rapp T, Müller WA

Abstract

暂无摘要

MeSH Terms

Adult Biological Availability Half-Life Hepatitis/metabolism Humans Kinetics Liver Cirrhosis, Alcoholic/metabolism Liver Diseases/metabolism Middle Aged Valerates/metabolism Valproic Acid/metabolism

Chemicals

Valerates Valproic Acid

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Klotz U

Rapp T

Müller W A

References (22)

22 references, click to expand

The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.
Clin Sci. 1961 Aug;21:43-57 PMID: 13689739
Drug disposition and liver disease.
Drug Metab Rev. 1975;4(2):139-75 PMID: 770104
Classification of cirrhosis.
Am J Gastroenterol. 1975 Dec;64(6):437-51 PMID: 1221828
Pharmacokinetics of di-n-propylacetate in epileptic patients.
Eur J Clin Pharmacol. 1975 Feb 28;8(2):97-105 PMID: 786678
Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.
Drugs. 1977 Feb;13(2):81-123 PMID: 402258
Pharmacokinetic studies with valproic acid in man.
Arzneimittelforschung. 1977;27(5):1085-8 PMID: 328019
Blood levels of drug at the equilibrium state after multiple dosing.
Nature. 1965 Sep 18;207(5003):1301-2 PMID: 5884654
[Pharmacokinetics of glymidine (glycodiazine) and tolbutamide in acute and chronic liver diseases].
Arzneimittelforschung. 1973 Dec;23(12):1801-7 PMID: 4801689
Influence of acute viral hepatitis on phenytoin kinetics and protein binding.
Clin Pharmacol Ther. 1975 Jun;17(6):685-91 PMID: 1139859
[Problems in serum-level determination during valproic acid therapy].
Arzneimittelforschung. 1977;27(6):1215-21 PMID: 332187
The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.
J Pharmacol Exp Ther. 1973 Jul;186(1):114-22 PMID: 4198771
Metabolism of amylobarbitone in patients with chronic liver disease.
Br J Pharmacol. 1972 Mar;44(3):549-60 PMID: 5040665
[Hepatoprotective and hepatoregenerative effects of di-n-propylacetic molecules].
Therapie. 1967 May-Jun;22(3):631-9 PMID: 6063441
Disposition of valproic acid in man.
Eur J Clin Pharmacol. 1977 Oct 14;12(2):125-32 PMID: 336377
Clearance concepts in pharmacokinetics.
J Pharmacokinet Biopharm. 1973 Apr;1(2):123-36 PMID: 4764426
The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
J Clin Invest. 1975 Feb;55(2):347-59 PMID: 1127104
Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review.
Epilepsia. 1975 Nov;16(4):549-73 PMID: 812693
Concentration of dipropylacetate in plasma.
Epilepsia. 1975 Nov;16(4):609-15 PMID: 1107022
Pharmacokinetics and bioavailability of sodium valproate.
Clin Pharmacol Ther. 1977 Jun;21(6):736-43 PMID: 324695
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.
Br J Clin Pharmacol. 1976 Apr;3(2):243-9 PMID: 973958
Time integral of drug concentration in the central (plasma) compartment.
J Pharm Sci. 1970 May;59(5):722-3 PMID: 5446439
Normal disposition of oxazepam in acute viral hepatitis and cirrhosis.
Ann Intern Med. 1976 Apr;84(4):420-5 PMID: 769632

Article Info

Journal

European journal of clinical pharmacology

Abbr.

Eur J Clin Pharmacol

ISSN

0031-6970

DOI

10.1007/BF00606683

Published

1978-03-17

Pages

55-60

Language

English

Region

Germany

NLM ID

1256165

Subset

External Links

PubMed source DOI: 10.1007/BF00606683 View journal details

Analysis Services

Disposition of valproic acid in patients with liver disease.

Contact

WeChat Official Account